Tom Gelzleichter - Senior Fellow / Toxicologist, Safety Assessment

Tom Gelzleichter

Senior Fellow / Toxicologist, Safety Assessment

"The only way you survive is you continuously transform into something else. It’s this idea of continuous transformation that makes for an innovation company."
Years at Genentech
Publications at Genentech

Following completion of postdoctoral training in toxicology, I joined Genentech as a Scientist in 1999. At that time, Genentech was emerging as a biotechnology powerhouse in the pharmaceutical industry and was renowned for innovative approaches to drug development. I have been fortunate to have served as a project team toxicologist where I designed and implemented non-clinical safety studies to support drug research and development efforts. This includes development of drugs for various disease classes including oncology, immunology, pulmonary, cardiovascular and metabolic diseases. I currently serve as Therapeutic Area Lead for metabolic disease and legacy programs and act as an advisor for the Global Technical Development organization.

Featured Publication

Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function or change in bile acid composition.

Toxicol. Sci. 140(2), 470-80.

Gelzleichter TR, Halpern W, Erwin R, Baruch A, Leabman M, Forrest AS, Satterwhite CM, Peng Kun, Chilton J, and Stevens D (2014).